Huntingtin toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1

被引:292
作者
Meriin, AB
Zhang, XQ
He, XW
Newnam, GP
Chernoff, YO
Sherman, MY
机构
[1] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA
[2] MIT, Cambridge, MA 02139 USA
[3] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA
[4] Georgia Inst Technol, Inst Bioengn & Biosci, Atlanta, GA 30332 USA
关键词
aggregation; polyglutamine; toxicity; prions; yeast;
D O I
10.1083/jcb.200112104
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The cause of Huntington's disease is expansion of polyglutamine (polyQ domain in huntingtin, which makes this protein both neurotoxic and aggregation prone. Here we developed the first yeast model, which establishes a direct link between aggregation of expanded polyQ domain and its cytotoxicity. Our data indicated that deficiencies in molecular chaperones Sis1 and Hsp104 inhibited seeding of polyQ aggregates, whereas ssa1, ssa2, and ydj7-151 mutations inhibited expansion of aggregates. The latter three mutants strongly suppressed the polyQ toxicity. Spontaneous mutants with suppressed aggregation appeared with high frequency, and in all of them the toxicity was relieved. Aggregation defects in these mutants and in sis7-85 were not complemented in the cross to the hsp704 mutant, demonstrating an unusual type of inheritance. Since Hsp104 is required for prion maintenance in yeast, this suggested a role for prions in polyQ aggregation and toxicity. We screened a set of deletions of nonessential genes coding for known prions and related proteins and found that deletion of the RNQ1 gene specifically suppressed aggregation and toxicity of polyQ. Curing of the prion form of Rnq1 from wild-type cells dramatically suppressed both aggregation and toxicity of polyQ. We concluded that aggregation of polyQ is critical for its toxicity and that Rnq1 in its prion conformation plays an essential role in polyQ aggregation leading to the toxicity.
引用
收藏
页码:997 / 1004
页数:8
相关论文
共 46 条
[1]   Intracellular localization of proteasomal degradation of a viral antigen [J].
Antón, LC ;
Schubert, U ;
Bacík, I ;
Princiotta, MF ;
Wearsch, PA ;
Gibbs, J ;
Day, PM ;
Realini, C ;
Rechsteiner, MC ;
Bennink, JR ;
Yewdell, JW .
JOURNAL OF CELL BIOLOGY, 1999, 146 (01) :113-124
[2]   Transgenic mice in the study of polyglutamine repeat expansion diseases [J].
Bates, GP ;
Mangiarini, L ;
Davies, SW .
BRAIN PATHOLOGY, 1998, 8 (04) :699-714
[3]   Mechanisms of chaperone suppression of polyglutamine disease:: selectivity, synergy and medullation of protein solubility in Drosophila [J].
Chan, HYE ;
Warrick, JM ;
Gray-Board, GL ;
Paulson, HL ;
Bonini, NM .
HUMAN MOLECULAR GENETICS, 2000, 9 (19) :2811-2820
[4]  
Chernoff YO, 1999, MOL CELL BIOL, V19, P8103
[5]   ROLE OF THE CHAPERONE PROTEIN HSP104 IN PROPAGATION OF THE YEAST PRION-LIKE FACTOR [PSI(+)] [J].
CHERNOFF, YO ;
LINDQUIST, SL ;
ONO, B ;
INGEVECHTOMOV, SG ;
LIEBMAN, SW .
SCIENCE, 1995, 268 (5212) :880-884
[6]   Mutation processes at the protein level: is Lamarck back? [J].
Chernoff, YO .
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2001, 488 (01) :39-64
[7]   Progress in pathogenesis studies of spinocerebellar ataxia type 1 [J].
Cummings, CJ ;
Orr, HT ;
Zoghbi, HY .
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES, 1999, 354 (1386) :1079-1081
[8]   Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice [J].
Cummings, CJ ;
Reinstein, E ;
Sun, YL ;
Antalffy, B ;
Jiang, YH ;
Ciechanover, A ;
Orr, HT ;
Beaudet, AL ;
Zoghbi, HY .
NEURON, 1999, 24 (04) :879-892
[9]   Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation [J].
Davies, SW ;
Turmaine, M ;
Cozens, BA ;
DiFiglia, M ;
Sharp, AH ;
Ross, CA ;
Scherzinger, E ;
Wanker, EE ;
Mangiarini, L ;
Bates, GP .
CELL, 1997, 90 (03) :537-548
[10]   Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? [J].
Davies, SW ;
Beardsall, K ;
Turmaine, M ;
DiFiglia, M ;
Aronin, N ;
Bates, GP .
LANCET, 1998, 351 (9096) :131-133